Testosterone Therapy for Women: Benefits, Risks, and What Doctors Won't Tell You

When most people hear "testosterone therapy," they picture men. But women produce testosterone too — and when levels decline, the effects are real, wide-ranging, and frequently dismissed in a standard OB-GYN or primary care visit. Low libido, persistent fatigue, brain fog, mood changes, and diminished muscle tone are not simply "part of aging." For many women, they are symptoms of an identifiable hormone deficiency with an evidence-based treatment. Here's what the current science says — and why so many women are still being left in the dark.

Why Women Need Testosterone

Testosterone is often framed as the "male hormone," but women's ovaries and adrenal glands produce it throughout life. In women, total testosterone typically ranges from 15–70 ng/dL — roughly 10–20× lower than men's levels, but biologically significant. Testosterone contributes to sexual desire and arousal, energy and motivation, bone mineral density, lean muscle maintenance, cognitive sharpness, and mood regulation.

Testosterone levels in women begin declining in the mid-20s and drop sharply at menopause when the ovaries significantly reduce production. Surgical menopause (oophorectomy) can cause an abrupt 50%+ decline overnight. Oral contraceptives suppress testosterone by raising sex hormone-binding globulin (SHBG), which binds and inactivates free testosterone — yet this effect is rarely discussed when pills are prescribed.

Hypoactive Sexual Desire Disorder (HSDD): The Most Under-Diagnosed Diagnosis

Hypoactive Sexual Desire Disorder (HSDD) — characterized by persistently low sexual desire that causes personal distress — affects an estimated 8–10% of women across all age groups and up to 30–40% of postmenopausal women. It is the most common female sexual dysfunction and one of the least aggressively treated.

The International Society for the Study of Women's Sexual Health (ISSWSH) published a comprehensive process-of-care algorithm in 2019 recommending testosterone therapy as a first-line consideration for postmenopausal women with HSDD. This was a landmark guidance document — the first formal professional endorsement of off-label testosterone use in women based on a systematic review of the evidence.

What the Evidence Actually Shows

The landmark evidence base for female testosterone therapy was crystallized in a 2019 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology by Davis et al. The analysis pooled data from 36 randomized controlled trials covering 8,480 women and reached several important conclusions:

• Testosterone significantly improved sexual function scores, including desire, arousal, orgasm frequency, and satisfaction, compared to placebo or estrogen alone
• Benefits were observed across premenopausal, perimenopausal, and postmenopausal women
• Short-term adverse effects were minor — mainly mild acne and increased body hair at higher doses
• No significant negative effects on cardiovascular markers, liver function, mood, or cognitive outcomes were observed at physiological doses
• The authors concluded that testosterone therapy is "efficacious for postmenopausal women with low sexual desire causing distress"

Davis SR, Baber R, Panay N, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." Lancet Diabetes Endocrinol. 2019;7(10):754–762.

This global consensus position was jointly endorsed by ISSWSH, the International Menopause Society (IMS), and the European Menopause and Andropause Society (EMAS), among others — lending it unusual multi-society authority.

The Off-Label Reality

Here's what most doctors won't tell you: there is currently no FDA-approved testosterone product specifically indicated for women in the United States. The one product that was — Intrinsa, a testosterone patch — was rejected by the FDA in 2004 primarily due to concerns about long-term cardiovascular data, not efficacy, and was never marketed in the US (though it was approved and used in Europe).

This regulatory gap means that despite strong evidence and multi-society endorsement, women who want testosterone therapy in the US must receive it via compounded formulations or via off-label use of male testosterone products at fraction-of-standard doses. Many conventional physicians, uncomfortable with off-label prescribing, simply don't offer it — leaving women without treatment for a condition with a proven solution.

Delivery Methods: Pellets vs. Cream vs. Injectable

Women's testosterone therapy requires careful dosing — the therapeutic window is narrow, and supraphysiological levels can cause unwanted virilizing effects (acne, hair growth, voice changes). Delivery method significantly affects both the precision of dosing and the management of side effects.

Topical Creams and Gels

Compounded topical testosterone cream is the most widely used delivery method for women. Typical doses are 0.5–2 mg daily applied to the inner arm, thigh, or vulvar area. Advantages include easy dose adjustment, no needles, and gradual onset. Disadvantages include variable absorption (affected by skin thickness, body fat, sweating), and the risk of transference to partners or children through skin contact.

Subcutaneous Pellets

Pellet therapy involves implanting a small rice-sized testosterone pellet under the skin of the hip or buttock every 3–6 months. Pellets provide steady-state delivery without daily dosing — appealing for compliance. The significant drawback is inflexibility: once inserted, the dose cannot be adjusted. If a woman responds with supraphysiological levels or unwanted side effects, the pellet must be removed or she must wait for it to dissolve. Pellet dosing errors in women are not uncommon in clinical practice and can result in weeks to months of elevated androgen levels.

Injectable Testosterone

Testosterone cypionate or enanthate, used in tiny doses (typically 5–20 mg weekly via subcutaneous injection rather than the 100–200 mg intramuscular doses used in male TRT), provides good dose control and is very cost-effective. Levels can be monitored with weekly labs early in treatment to fine-tune the dose. The weekly injection schedule is a barrier for some women but is otherwise an excellent option for provider-supervised therapy.

Monitoring, Safety, and What to Expect

Before initiating testosterone therapy, a full hormone panel is essential: total testosterone, free testosterone, SHBG, estradiol, FSH, LH, and a complete metabolic panel. Baseline lipids and hematocrit should also be checked, as testosterone can increase red blood cell production.

Follow-up labs at 6–8 weeks allow dose adjustment to bring total testosterone into the target range for premenopausal women (typically 15–70 ng/dL, with free testosterone as a key guide). Most women with HSDD or fatigue symptoms begin noticing improvement in libido and energy within 4–8 weeks of reaching therapeutic levels.

Long-term safety data in women remains more limited than in men, which is why the Davis et al. consensus statement called for more research on cardiovascular and breast cancer outcomes beyond two years. Current evidence does not suggest increased breast cancer risk at physiological testosterone doses — and some data suggests testosterone may be protective — but this remains an active area of study. Women with a personal or strong family history of hormone-sensitive cancers should discuss the risk-benefit profile carefully with their provider.

The Bottom Line

Testosterone is not just a man's hormone. It is a critical driver of sexual health, energy, and well-being in women — and its decline is a legitimate medical issue, not something to be dismissed or told to "just live with." The evidence base is strong enough that multiple major international societies have formally endorsed its use. The primary barrier for most women is simply finding a provider who is knowledgeable, comfortable with compounded formulations, and willing to treat based on symptoms and evidence rather than the absence of an FDA label.

If you've been told your symptoms are "just menopause" without a hormone evaluation, it may be time to seek a second opinion from a provider with expertise in hormonal health.